Deciphera Pharmaceuticals, Inc. (DCPH)
| Market Cap | 470.19M |
| Revenue (ttm) | 91.44M |
| Net Income (ttm) | -274.31M |
| Shares Out | 58.48M |
| EPS (ttm) | -4.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,301,664 |
| Open | 8.12 |
| Previous Close | 8.15 |
| Day's Range | 8.02 - 8.37 |
| 52-Week Range | 7.63 - 52.43 |
| Beta | 1.51 |
| Analysts | Buy |
| Price Target | 12.22 (+52.0%) |
| Earnings Date | Feb 7, 2022 |
About DCPH
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for DCPH stock is "Buy." The 12-month stock price forecast is 12.22, which is an increase of 51.99% from the latest price.
News
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...
Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. ...
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stro...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...
Deciphera: Why There Won't Be a Quick Recovery
Traders might look at DCPH stock for a quick bounce after its 75% decline. But here's why that's not a great idea.
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 78.5% Since Last Earnings Report?
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?
Deciphera (DCPH) to Prioritize Key Pipeline Drugs, Cut Jobs
Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.
Why Deciphera Pharmaceuticals Shot 12% Higher Today
The company announced a comprehensive restructuring program.
Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard
Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials.
Deciphera Pharma Stock Rises After Announcing Corporate Restructuring
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) will undergo a corporate restructuring to eliminate 35% of its workforce and end a Phase 1/2 program for solid tumors. Deciphera will implement an organizati...
Don't Bet on a Deciphera Stock Comeback
Qinlock's potential is severely limited, and the rest of Deciphera's pipeline is far from the commercialization stage. With this, expect DCPH stock to remain a clear-cut "avoid" situation.
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commerci...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...
Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.
Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST
The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.
Deciphera's Qinlock Approved In Europe For Gastric Cancer
The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ: DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior tre...
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...
Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals
Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip.
DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plunging 70%?
Today, investors in Deciphera Pharmaceuticals and DCPH stock have seen tremendous selling pressure take this stock to all-time lows. The post DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plunging ...
Deciphera Pharmaceuticals opened 75% down on Friday: explore why
Shares of Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) tanked 75% on Friday morning after the U.S. firm said its INTRIGUE Phase III Clinical Study failed to meet the primary endpoint. The sharp decline ...
Why Did Deciphera Stock Plunged 70% Today?
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in patients with gastrointestinal stromal tumor ...
Why Did Deciphera Stock Plunge 70% Today?
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in patients with gastrointestinal stromal tumor ...
Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...
Deciphera (DCPH) Q3 Loss Wider Than Expected, Revenues Miss
Deciphera (DCPH) reports wider-than-expected loss and revenue miss in the third quarter. It is gearing up for multiple developments and pipeline updates in the fourth quarter.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -6.20% and -2.14%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for...
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update. “In the t...
Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on No...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its third quarter 2021 financial results on Tuesday, November 2, 2021. In connection w...